Equities

Rapport Therapeutics Inc

RAPP:NMQ

Rapport Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)23.13
  • Today's Change0.83 / 3.72%
  • Shares traded76.61k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 25 2024 18:26 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a portfolio of precision small molecule product candidates. The Company focuses on developing a new class of precision neuromedicines aimed at providing patients with alternatives to existing treatments for central nervous system disorders. It advances a pipeline of therapeutic programs to patients living with central nervous system (CNS) disorders, including focal onset epilepsy, pain, bipolar disorder, and hearing disorders. Its program ionotropic receptors for glutamate (iGluR) are ligand gated ion channels activated by the neurotransmitter glutamate. Its RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPy8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy.

  • Revenue in USD (TTM)0.00
  • Net income in USD-51.31m
  • Incorporated2022
  • Employees58.00
  • Location
    Rapport Therapeutics Inc1325 Boylston Street, Suite 401BOSTON 02215United StatesUSA
  • Phone+1 (857) 321-8020
  • Fax+1 (302) 655-5049
  • Websitehttps://www.rapportrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Prime Medicine Inc591.00k-204.50m748.99m234.00--3.07--1,267.33-2.17-2.170.00622.030.0019----2,525.64-65.09---70.51-------34,601.86------0.00-------39.52------
Dianthus Therapeutics Inc3.22m-50.21m749.00m53.00--2.01--232.32-3.20-3.200.272112.700.0138----60,830.19-21.56-41.40-22.27-44.70-----1,557.51-12,132.27----0.00------43.04---57.21--
Harrow Inc138.68m-31.33m760.00m315.00--12.55--5.48-0.9079-0.90794.091.710.54064.216.75440,244.40-12.21-10.86-13.79-12.7169.7770.75-22.59-15.352.75-0.33020.7536--46.9525.77-73.30--143.88--
ARS Pharmaceuticals Inc10.00k-49.70m798.42m24.00--3.55--79,841.69-0.5198-0.51980.00012.320.00004----416.67-19.93-20.37-20.48-21.32-----496,960.00-17,491.75----0.00---97.72---56.75---17.18--
Longboard Pharmaceuticals Inc0.00-57.95m809.48m50.00--2.58-----2.25-2.250.008.070.00----0.00-28.45---29.73--------------0.00-------23.84------
Aurinia Pharmaceuticals Inc191.41m-62.56m809.49m300.00--2.26--4.23-0.4363-0.43631.342.500.39530.60087.98638,023.30-12.92-25.97-14.63-28.2488.78---32.69-137.645.05--0.1843--30.95227.9027.88--57.11--
Ginkgo Bioworks Holdings Inc208.70m-853.81m809.77m1.22k--0.7543--3.88-0.4347-0.43470.10610.48550.1044--3.82171,344.00-42.70---46.94--80.43---409.12------0.00---47.36--57.58------
Rapport Therapeutics Inc0.00-51.31m815.66m58.00---------1.45-1.450.005.52------0.00--------------------0.00-------226.57------
AbCellera Biologics Inc35.79m-146.90m820.41m586.00--0.725--22.92-0.5056-0.50560.12323.850.0242--1.3261,071.67-9.926.08-10.626.67-----410.4724.697.75--0.000.00-92.1733.91-192.35--70.96--
89bio Inc0.00-165.03m831.34m70.00--1.58-----2.01-2.010.005.360.00----0.00-30.80-45.50-32.70-49.31------------0.0466-------39.37---36.58--
Viridian Therapeutics Inc288.00k-218.13m843.09m96.00--2.20--2,927.41-4.50-4.500.00589.130.0006--2.503,063.83-42.89-55.59-45.38-60.32-----75,737.84-5,678.12----0.0337---82.28-48.16-83.05--15.08--
Cogent Biosciences Inc0.00-212.17m850.00m164.00--4.25-----2.47-2.470.004.420.00----0.00-57.40-49.53-62.27-54.94-------1,684.44----0.00-------37.20--38.48--
USANA Health Sciences, Inc.900.45m61.94m868.90m1.80k14.241.7411.660.9653.203.2046.5626.251.462.73--500,250.0010.0316.2312.4921.7580.9881.426.888.963.20--0.00260.00-7.77-4.98-8.02-12.764.86--
Gyre Therapeutics Inc140.62m-85.66m881.61m593.00--15.55--6.27-1.88-1.881.550.6632.00--13.75237,136.60-107.71-73.59-184.22-99.9496.01---53.91-205.622.97--0.00--14,188.41616.69-1,027.55--86.95--
Data as of Jun 25 2024. Currency figures normalised to Rapport Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.